MDXH.BR - MDxHealth SA

Brussels - Brussels Delayed Price. Currency in EUR
0.7130
+0.0060 (+0.85%)
At close: 5:23PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.7070
Open0.7050
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7000 - 0.7150
52 Week Range0.5120 - 1.4000
Volume26,668
Avg. Volume85,087
Market Cap50.287M
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.6890
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      MDxHealth Announces its Special and Extraordinary General Shareholders’ Meetings

      IRVINE, CA, and HERSTAL, BELGIUM – 30 June 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, today invites the holders of securities issued by the Company to its special and extraordinary general shareholders' meetings that will be held on Thursday 30 July 2020 at 1:00 p.m., Belgian time. The items on the agenda of the special and extraordinary general shareholders' meetings include the proposed appointment of new directors and change in the directors' remuneration, as well as the renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital and the adoption of an amended and restated version of the articles of associations in accordance with the provisions of the Belgian Companies and Associations Code and reflecting some technical changes.

    • GlobeNewswire

      MDxHealth Shareholder Transparency Declarations

      IRVINE, CA, and HERSTAL, BELGIUM – 4 June 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that on 2 June 2020 it received the following notification of significant shareholdings as a consequence of the capital increase completed on 15 May 2020. Scorpiaux BVBA notified MDxHealth that the aggregate number of shares with respect to which Scorpiaux BVBA can exercise voting rights passively crossed below the threshold of 5% of the outstanding shares and voting rights of MDxHealth.

    • GlobeNewswire

      MDxHealth Announces Results of Annual and Extraordinary General Shareholders' Meetings

      IRVINE, CA, and HERSTAL, BELGIUM – 28 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM"). As the required attendance quorum for the EGM was not met, a new EGM will be held on 30 July 2020 (unless decided otherwise by the Company). Exceptionally, and in accordance with the Belgian Royal Decree no. 4 of 9 April 2020 on miscellaneous provisions relating to co-ownership and corporate and association law in the context of the fight against the COVID-19 pandemic, the AGM and EGM were held behind closed doors without the physical presence of the holders of securities of the Company and their representatives.

    • GlobeNewswire

      MDxHealth's New Share Capital Amount and New Number of Shares

      Press release Regulated information 25 May 2020 20:00  CEST IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or.

    • GlobeNewswire

      MDxHealth Completes the Equity Investment by MVM Partners

      IRVINE, CA, and HERSTAL, BELGIUM – 15 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces today that MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively "MVM"), completed their equity investment in the Company for an aggregate amount of EUR 12,738,632.94 (or approximately $13.7 Million). As a result of the investment, the Company's share capital was increased from EUR 56,260,102.01 to EUR 68,998,734.95, through the issuance of 20,162,924 new ordinary shares of the Company at an issue price of (rounded) EUR 0.632 per share.

    • GlobeNewswire

      MDxHealth Announces its Annual and Extraordinary General Shareholders’ Meetings

      IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, today invites the holders of securities issued by the Company to its annual and extraordinary general shareholders' meetings that will be held on Thursday 28 May 2020 at 10:00 a.m., Belgian time. The items on the agenda of the annual and extraordinary general shareholders' meetings include the proposed approval of a number of resolutions relating to the financial year ended on 31 December 2019, as well as the renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital and the adoption of an amended and restated version of the articles of associations in accordance with the provisions of the Belgian Companies and Associations Code and reflecting some technical changes.

    • GlobeNewswire

      MDxHealth Announces Growth Investment from MVM Partners

      IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces today that it entered into a subscription agreement with MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively "MVM"), pursuant to which MVM has agreed to provide an equity investment to the Company for an aggregate amount of EUR 12,738,632.94 (or approximately $14 Million). The equity investment will consist of a subscription of 20,162,924 new ordinary shares of the Company at an issue price of EUR 0.632 per share, representing a 5% discount to the 45-day volume weighted average price.

    • GlobeNewswire

      MDxHealth to Receive $2.3 million “Paycheck Protection Program” Loan Under the U.S. CARES Act

      April 20, 2020 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2.3 million as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act.

    • GlobeNewswire

      MDxHealth Provides Q1-2020 Business Update

      April 9, 2020 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the first quarter ended March 31, 2020. Product revenues in the first quarter of 2020 increased by 26% compared to Q1-2019 and ConfirmMDx units, while impacted in March by the COVID-19 outbreak, were still up 3% from the same period last year. Despite the unavoidable challenges presented by this pandemic, MDxHealth’s compelling value proposition, strong business fundamentals and emphasis on focus and execution remains unchanged.

    • GlobeNewswire

      MDxHealth Updates 2020 Reporting Calendar and Provides Initial View on Coronavirus Situation

      April 1, 2020 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today updated its 2020 reporting calendar, moving its Q1 business update forward to April 9th from April 21st. In the context of the novel coronavirus (COVID-19) pandemic, MDxHealth expects that the global measures taken to contain the virus may potentially impact the FY2020 outlook of the Company as published on February 26, 2020 with its FY2019 results. The Company is monitoring the situation closely and will provide more information in due course.

    • GlobeNewswire

         MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

      February 26, 2020 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the year ended December 31, 2019 and provided a business update and outlook for 2020.

    • Did Changing Sentiment Drive MDxHealth's (EBR:MDXH) Share Price Down A Painful 79%?
      Simply Wall St.

      Did Changing Sentiment Drive MDxHealth's (EBR:MDXH) Share Price Down A Painful 79%?

      As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like...

    • GlobeNewswire

      MDxHealth Provides Q3-2019 Business Update

      November 11, 2019 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019. Michael McGarrity, CEO of MDxHealth, said: “During this transitional period for MDxHealth we have set a foundation that will enable us to drive growth into our best in class menu which provides a pathway for both clinicians and patients screened for prostate cancer. This confidence is based in the actions we have taken to strengthen and focus our commercial organization and our ability to leverage the following key areas, which will be the catalyst for our growth projections.

    • GlobeNewswire

      MDxHealth Shareholder Transparency Declaration

      IRVINE, CA, and HERSTAL, BELGIUM – 10 October 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or "MDxHealth"), a commercial-stage innovative molecular diagnostics.

    • GlobeNewswire

      MDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase

      IRVINE, CA, and HERSTAL, BELGIUM – 27 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces the successful pricing of its capital increase with the offering of new ordinary shares. The Company raised EUR 9.0 million (USD 9.8 million)(1) in gross proceeds by means of a private placement of 10,589,236 new shares at an issue price of EUR 0.85 per share through an accelerated bookbuilding (the "Capital Increase"). Michael McGarrity, CEO of MDxHealth, said: "We are pleased to have secured additional funding from a mix of new and existing investors, demonstrating confidence in our ability to realize the Company's growth potential by delivering on several clearly identified value drivers.

    • GlobeNewswire

      MDxHealth Launches Capital Increase and Secures Debt Financing from Kreos Capital

      IRVINE, CA, and HERSTAL, BELGIUM – 26 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces the launch of a capital increase with the offering of new ordinary shares by means of a private placement (the "Capital Increase") and the entering into a loan agreement with Kreos Capital (the "Debt Financing"). MDxHealth is singularly focused on execution of its commercial and operating strategy, and sees initial results of this focus in the first two months of the current quarter, with growth of billed patient test volumes for ConfirmMDx versus both the first two months of Q3 2018 as well as versus the first two months of the last quarter.

    • How MDxHealth SA (EBR:MDXH) Can Impact Your Portfolio Volatility
      Simply Wall St.

      How MDxHealth SA (EBR:MDXH) Can Impact Your Portfolio Volatility

      Anyone researching MDxHealth SA (EBR:MDXH) might want to consider the historical volatility of the share price...

    • GlobeNewswire

      MDxHealth Reports Half Year 2019 Financial Results and Strategic Update

      Conference call with Q&A today at 11:00 CEST / 10:00 BST, details provided below IRVINE, CA, and HERSTAL, BELGIUM– August 29, 2019 – MDxHealth SA (Euronext: MDXH.BR), a.

    • MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test
      PR Newswire

      MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test

      IRVINE, Calif., Aug. 26, 2019 /PRNewswire/ -- MDxHealth SA (Euronext:MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDx program, has issued a draft local coverage determination (LCD) for the SelectMDx® for Prostate Cancer test. The draft LCD recommends coverage of the test for qualified Medicare patients throughout the United States. "We are pleased that Medicare has taken this important step toward providing coverage for SelectMDx — a test that can help improve the disposition of men at risk for aggressive prostate cancer," stated Michael McGarrity, CEO of MDxHealth.

    • GlobeNewswire

      MDxHealth (R): MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test

      August 26, 2019 – MDxHealth SA (MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDx program, has issued a draft local coverage determination (LCD) for the SelectMDx® for Prostate Cancer test. The draft LCD recommends coverage of the test for qualified Medicare patients throughout the United States. “We are pleased that Medicare has taken this important step toward providing coverage for SelectMDx — a test that can help improve the disposition of men at risk for aggressive prostate cancer,” stated Michael McGarrity, CEO of MDxHealth.

    • GlobeNewswire

      MDxHealth: MDxHealth Notice of Interim Results 2019

      REGULATED INFORMATION Conference call for analysts and investors to be held on 29 August 2019 at 11.00 CEST IRVINE, CA, and HERSTAL, BELGIUM – 07.00 CEST, 23 August 2019 –.

    • Do Directors Own MDxHealth SA (EBR:MDXH) Shares?
      Simply Wall St.

      Do Directors Own MDxHealth SA (EBR:MDXH) Shares?

      If you want to know who really controls MDxHealth SA (EBR:MDXH), then you'll have to look at the makeup of its share...